Federal well being officers say many circumstances of blood clots linked to the AstraZeneca coronavirus vaccine are much less harmful than beforehand thought.
The Therapeutic Items Administration, utilizing standards proposed by US well being officers, divides blood clot studies into two tiers, separating people who happen in an “uncommon” location within the physique from people who happen in a “standard” one.
Uncommon locations to undergo blood clots embody the mind or stomach, whereas standard locations embody legs or lungs.
Out of the 48 confirmed and possible circumstances of clots, solely 15 are within the first class.
“Australian circumstances appear to characterize a wider spectrum of illness than seen in different nations with extra blood clots in frequent areas equivalent to deep vein thrombosis within the leg and pulmonary embolism within the lungs,” a well being division spokesman mentioned.
“Whereas in some circumstances such clots are severe, in lots of circumstances they’re much less severe than the uncommon clotting syndrome initially reported, which largely concerned clots within the mind and stomach.”
On Thursday, a NSW girl turned the second particular person to die from the so-called thrombosis with thrombocytopenia syndrome, or TTS, that has been related to the AstraZeneca coronavirus vaccine.
Whereas regarding, the syndrome may be very uncommon. The 48 Australian circumstances come out of greater than 3.6 million AstraZeneca doses administered.
For comparability, the coronavirus itself has killed over 2 per cent of the greater than 173 million individuals who have been contaminated.
supply : information.google.com
قد يهمك أيضاً :-
- Development in 1999 sleeping bikie murder
- England vaccine target moved forward - as AstraZeneca jab reconsidered for young
- U.K. expected to delay reopening as Delta variant accounts for 90% of cases and U.S. court upholds mandatory vaccination
- Race to double jab 10m in four weeks
- ScoMo denies QAnon cult links
- Crazy 52km traffic jam towards Sydney
- Novavax: Large study finds COVID-19 shot about 90% effective